Judicious Measures Are The Key To Dampening China's Sizzling Growth, Says Article May 07

  • ID: 2165764
  • May 2007
  • Region: China
  • Standard & Poors
1 of 3

Hong Kong (Standard & Poor's) May 24, 2007--China's central bank needs to sharpen its knives. Monetary tightening measures have so far failed to rein back runaway economic growth or stop share prices from reaching vertigo-inducing heights. Further measures expected in the second half of 2007 are likely to have only a limited cooling effect. That's according to an article released today by Standard & Poor's Ratings Services titled "Can China's Central Bank Do More Than Roar As Growth Soars?". The article explains that a judicious mix of interest, exchange, and reserve rate adjustments, as well as direct administrative measures, will be the key to dampening unsustainable growth and safeguarding long-term stability. "A heavy-handed approach, however, could have a significantly negative...

Companies mentioned in this report are: China (People's Republic of )
Action: General Comment

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

China (People's Republic of )

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.